JP2004536066A5 - - Google Patents

Download PDF

Info

Publication number
JP2004536066A5
JP2004536066A5 JP2002591462A JP2002591462A JP2004536066A5 JP 2004536066 A5 JP2004536066 A5 JP 2004536066A5 JP 2002591462 A JP2002591462 A JP 2002591462A JP 2002591462 A JP2002591462 A JP 2002591462A JP 2004536066 A5 JP2004536066 A5 JP 2004536066A5
Authority
JP
Japan
Prior art keywords
methyl
pyrrolidin
alkyl
hydrogen
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002591462A
Other languages
English (en)
Japanese (ja)
Other versions
JP3715280B2 (ja
JP2004536066A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/005120 external-priority patent/WO2002094789A1/en
Publication of JP2004536066A publication Critical patent/JP2004536066A/ja
Publication of JP2004536066A5 publication Critical patent/JP2004536066A5/ja
Application granted granted Critical
Publication of JP3715280B2 publication Critical patent/JP3715280B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002591462A 2001-05-21 2002-05-08 ニューロペプチドｙレセプターのリガンドとしてのキノリン誘導体 Expired - Fee Related JP3715280B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01112370 2001-05-21
PCT/EP2002/005120 WO2002094789A1 (en) 2001-05-21 2002-05-08 Quinoline derivatives as ligands for the neuropeptide y receptor

Publications (3)

Publication Number Publication Date
JP2004536066A JP2004536066A (ja) 2004-12-02
JP2004536066A5 true JP2004536066A5 (enExample) 2005-08-25
JP3715280B2 JP3715280B2 (ja) 2005-11-09

Family

ID=8177497

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002591462A Expired - Fee Related JP3715280B2 (ja) 2001-05-21 2002-05-08 ニューロペプチドｙレセプターのリガンドとしてのキノリン誘導体

Country Status (19)

Country Link
US (2) US6818767B2 (enExample)
EP (1) EP1395564B1 (enExample)
JP (1) JP3715280B2 (enExample)
KR (1) KR100621287B1 (enExample)
CN (1) CN100376557C (enExample)
AR (1) AR035979A1 (enExample)
AT (1) ATE387428T1 (enExample)
AU (1) AU2002338896B2 (enExample)
BR (1) BR0209957A (enExample)
CA (1) CA2446324A1 (enExample)
DE (1) DE60225274T2 (enExample)
ES (1) ES2300478T3 (enExample)
GT (1) GT200200090A (enExample)
MX (1) MXPA03010565A (enExample)
PA (1) PA8545301A1 (enExample)
PE (1) PE20021155A1 (enExample)
UY (1) UY27300A1 (enExample)
WO (1) WO2002094789A1 (enExample)
ZA (1) ZA200308783B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
AU2002352878B2 (en) * 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
WO2003066055A1 (en) * 2002-02-04 2003-08-14 F. Hoffmann-La Roche Ag Quinoline derivatives as npy antagonists
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
EP1560816A1 (en) 2002-07-05 2005-08-10 F. Hoffmann-La Roche Ag Quinazoline derivatives
RU2324685C2 (ru) 2002-08-07 2008-05-20 Ф.Хоффманн-Ля Рош Аг Производные тиазола, способ их получения и применение, фармацевтическая композиция, обладающая свойствами антагонистов рецепторов npy
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2518398A1 (en) * 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
AU2004289303A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
BRPI0610580B8 (pt) 2005-05-30 2021-05-25 Banyu Pharma Co Ltd composto derivado de piperidina
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
WO2007029847A1 (ja) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. 二環性芳香族置換ピリドン誘導体
EP1944301A4 (en) 2005-10-27 2012-01-04 Msd Kk NEW BENZOXATHIIN DERIVATIVES
ES2381205T3 (es) 2005-11-10 2012-05-24 Msd K.K. Derivado espiro aza-sustituido
WO2008020302A2 (en) * 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
US20090247560A1 (en) 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
WO2008141077A1 (en) * 2007-05-10 2008-11-20 Janssen Pharmaceutica N.V. Process for the preparation of tetrahydroquinolinyl, benzoxazine and benzothiazine derivatives
ES2637999T3 (es) * 2007-05-17 2017-10-18 Helperby Therapeutics Limited Uso de compuestos de 4-(pirrolidin-1-il)quinolina para eliminar microorganismos clínicamente latentes
CN101679853B (zh) * 2007-06-01 2013-10-30 E.I.内穆尔杜邦公司 用于绿色发光应用的*
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
ATE541841T1 (de) * 2007-11-15 2012-02-15 Boehringer Ingelheim Int Inhibitoren der replikation des human immunodeficiency virus
EA019259B1 (ru) 2007-11-16 2014-02-28 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
EP2264026A4 (en) 2008-03-06 2012-03-28 Msd Kk ALKYLAMINOPYRIDINDERIVATE
WO2009119726A1 (ja) 2008-03-28 2009-10-01 萬有製薬株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (en) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetic spirochroman compounds
US11344543B2 (en) * 2017-07-14 2022-05-31 Innate Tumor Immunity, Inc. NLRP3 modulators

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU43730A1 (enExample) * 1962-06-14 1963-07-13
US3272824A (en) * 1962-12-06 1966-09-13 Norwich Pharma Co 4-amino-6, 7-di(lower) alkoxyquinolines
US3812127A (en) * 1966-10-31 1974-05-21 Pfizer 4-(quinolin-4-yl)piperazine-1-carboxylic acid esters
US4035367A (en) * 1974-09-09 1977-07-12 Sandoz, Inc. Hydroxyalkyl-substituted-amino-quinolines
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
AU641215B2 (en) 1990-02-13 1993-09-16 Merrell Dow Pharmaceuticals Inc. Stabilized sulfonate, sulfate, phosphonate and phosphate derivatives of hirudin
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
EP0882717B1 (en) * 1996-10-01 2010-09-08 Kyowa Hakko Kirin Co., Ltd. Nitrogenous heterocyclic compounds
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
WO2000009123A1 (en) 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors and chitosan
TR200100471T2 (tr) 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri içeren farmasötik bileşimler
AU1047401A (en) * 1999-11-08 2001-06-06 Cytion Sa Apparatus and methods for positioning and analyzing biological membranous objects
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists

Similar Documents

Publication Publication Date Title
JP2004536066A5 (enExample)
JP3715280B2 (ja) ニューロペプチドｙレセプターのリガンドとしてのキノリン誘導体
JP2005523901A5 (enExample)
JP5450434B2 (ja) 関節炎の治療方法
JP2005508923A5 (enExample)
JP2004521087A5 (enExample)
JP2016538313A5 (enExample)
JP2003528917A5 (enExample)
JP2018511626A5 (enExample)
JP2020521740A5 (enExample)
JP2020512343A5 (enExample)
JP2004507527A5 (enExample)
JP2008521900A5 (enExample)
JP2005510473A5 (enExample)
JP2005508313A5 (enExample)
JP2004525965A5 (enExample)
AU2002338896A1 (en) Quinoline derivatives as ligands for the neuropeptide Y receptor
JP2004524279A5 (enExample)
CA2730471A1 (en) Piperazine derivatives used as cav2.2 calcium channel modulators
RU2019123319A (ru) Пиразолопиримидины и способы их применения
JP2005538111A5 (enExample)
TW402601B (en) Aminocycloalkylpyrrolidinyl-substituted quinolone derivatives having antibacterial effect and pharmaceutical composition containing them
JP2007506703A5 (enExample)
JP2008535803A5 (enExample)
RU2006120486A (ru) Гидроксиалкилзамещенные пиридо-7-пиримидин-7-оны